(MYGN) Myriad Genetics - Ratings and Ratios

Myriad Genetics, Inc. (NASDAQ:MYGN) is a leader in molecular diagnostic testing and precision medicine, specializing in the development and commercialization of innovative diagnostic products. The company focuses on advancing personalized medicine through its portfolio of genetic tests designed to assess risks for hereditary cancers, guide cancer therapy selection, and provide insights into various health conditions. Myriads offerings include the MyRisk Hereditary Cancer test, which uses DNA sequencing to evaluate genetic cancer risks; BRACAnalysis CDx, a companion diagnostic test for metastatic cancers linked to BRCA variants; and MyChoice CDx, which identifies homologous recombination deficiency in ovarian cancer patients.

The company also provides Prolaris, a prostate cancer prognostic test analyzing RNA expression to determine disease aggressiveness, and EndoPredict, a breast cancer prognostic test using RNA expression to assess tumor biology. Myriads portfolio extends to prenatal and mental health testing, including the Prequel Prenatal Screen for chromosomal disorders, Foresight Carrier Screen for genetic risk assessment, SneakPeek for early gender prediction, and GeneSight for psychotropic medication selection in mental health conditions. Collaborations with Illumina, Memorial Sloan Kettering, MD Anderson, and Flatiron Health underscore its commitment to advancing precision medicine.

Founded in 1991 and headquartered in Salt Lake City, Utah, Myriad Genetics operates at the intersection of genomics and healthcare, aiming to improve patient outcomes through actionable genetic insights. Its diverse product lineup addresses critical areas in oncology, womens health, and pharmacogenomics, positioning it as a key player in the molecular diagnostics industry.

Based on the provided and , Myriad Genetics stock (NASDAQ:MYGN) is currently trading below its 20-, 50-, and 200-day simple moving averages (SMA), indicating bearish momentum. The average true range (ATR) of 0.51 suggests moderate volatility. On a fundamental basis, the companys market cap of $696.82M and price-to-book (P/B) ratio of 0.99 indicate potential undervaluation. However, the negative return on equity (RoE) of -17.36% highlights financial challenges. The forward P/E of 97.09 reflects high expectations for future earnings growth. Overall, MYGN may present a recovery opportunity for long-term investors, but near-term price movements are likely to remain subdued due to technical resistance and profitability concerns.